Butenafine 1% cream in the treatment of tinea cruris: A multicenter, vehicle-controlled, double-blind trial

Jr Lesher, D. E. Babel, D. M. Stewart, T. M. Jones, L. Kaminester, M. Goldman, J. S. Weintraub

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Background: Butenafine hydrochloride, a potent antifungal agent related to the allylamines, has been used in Japan for treating various cutaneous mycoses including tinea cruris.Objective: We compared the safety and efficacy of butenafine hydrochloride and its vehicle when used once daily for 2 weeks to treat tinea cruris. Methods: Patients (n = 93) with tinea cruris and a positive potassium hydroxide examination and mycologic culture were enrolled. Of the 76 patients assessed for efficacy, 37 applied butenafine and 39 applied vehicle once daily for 2 weeks. Assessments were made at the end of the 2-week treatment period and 4 weeks after the end of treatment. Results: Patients in the butenafine group had a higher mycologic cure rate by day 7 (66% vs 13%, p < 0.0001), with marked improvement 4 weeks after the end of treatment (81% vs 13%, p < 0.0001). They also had a higher rate of effective treatment at day 7 (29% vs 5%, p < 0.01) and at 4 weeks after treatment (73% vs 5%, < 0.0001). Adverse events definitely related to butenafine treatment were limited to one case of burning sensation after application. Conclusion: Butenafine applied once daily for 2 weeks is effective in treating tinea cruris. The proportion of patients cured increased between the end of treatment and 4 weeks after treatment.

Original languageEnglish (US)
Pages (from-to)S20-S24
JournalJournal of the American Academy of Dermatology
Volume36
Issue number2
DOIs
Publication statusPublished - Feb 25 1997

    Fingerprint

ASJC Scopus subject areas

  • Dermatology

Cite this

Lesher, J., Babel, D. E., Stewart, D. M., Jones, T. M., Kaminester, L., Goldman, M., & Weintraub, J. S. (1997). Butenafine 1% cream in the treatment of tinea cruris: A multicenter, vehicle-controlled, double-blind trial. Journal of the American Academy of Dermatology, 36(2), S20-S24. https://doi.org/10.1016/S0190-9622(97)70318-9